WYETH-AYERST NORMIFLO LMWH APPROVAL "LIKELY" IN 1994/1995

Executive Summary

WYETH-AYERST NORMIFLO LMWH APPROVAL "LIKELY" IN 1994/1995, Wyeth-Ayerst Research President Robert Levy, MD, forecast in a presentation at the Bear Stearns Seventh Annual Health Care Conference in New York City Sept. 21. Normiflo low molecular weight heparin for the once-a-day treatment of coronary artery disease "has been at FDA for two years now," Levy told Bear Stearns conference attendees. "We feel we have answered all of the FDA's questions and we hope for approval within the next six months, hopefully by the end of the year."